Cargando…
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New findings, starting from our proteomics studies on IPF, suggest that systemic involvement with altered molecular mechanisms and metabolic disorder is an underlying cause of fibrosis. The role of metabolic dy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461042/ https://www.ncbi.nlm.nih.gov/pubmed/32784632 http://dx.doi.org/10.3390/ijms21165663 |
_version_ | 1783576709050662912 |
---|---|
author | Bargagli, Elena Refini, Rosa Metella d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Vantaggiato, Lorenza Bini, Luca Landi, Claudia |
author_facet | Bargagli, Elena Refini, Rosa Metella d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Vantaggiato, Lorenza Bini, Luca Landi, Claudia |
author_sort | Bargagli, Elena |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New findings, starting from our proteomics studies on IPF, suggest that systemic involvement with altered molecular mechanisms and metabolic disorder is an underlying cause of fibrosis. The role of metabolic dysregulation in the pathogenesis of IPF has not been extensively studied, despite a recent surge of interest. In particular, our studies on bronchoalveolar lavage fluid have shown that the renin–angiotensin–aldosterone system (RAAS), the hypoxia/oxidative stress response, and changes in iron and lipid metabolism are involved in onset of IPF. These processes appear to interact in an intricate manner and to be related to different fibrosing pathologies not directly linked to the lung environment. The disordered metabolism of carbohydrates, lipids, proteins and hormones has been documented in lung, liver, and kidney fibrosis. Correcting these metabolic alterations may offer a new strategy for treating fibrosis. This paper focuses on the role of metabolic dysregulation in the pathogenesis of IPF and is a continuation of our previous studies, investigating metabolic dysregulation as a new target for fibrosis therapy. |
format | Online Article Text |
id | pubmed-7461042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74610422020-09-14 Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis Bargagli, Elena Refini, Rosa Metella d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Vantaggiato, Lorenza Bini, Luca Landi, Claudia Int J Mol Sci Review Idiopathic pulmonary fibrosis (IPF) is a fibroproliferative disorder limited to the lung. New findings, starting from our proteomics studies on IPF, suggest that systemic involvement with altered molecular mechanisms and metabolic disorder is an underlying cause of fibrosis. The role of metabolic dysregulation in the pathogenesis of IPF has not been extensively studied, despite a recent surge of interest. In particular, our studies on bronchoalveolar lavage fluid have shown that the renin–angiotensin–aldosterone system (RAAS), the hypoxia/oxidative stress response, and changes in iron and lipid metabolism are involved in onset of IPF. These processes appear to interact in an intricate manner and to be related to different fibrosing pathologies not directly linked to the lung environment. The disordered metabolism of carbohydrates, lipids, proteins and hormones has been documented in lung, liver, and kidney fibrosis. Correcting these metabolic alterations may offer a new strategy for treating fibrosis. This paper focuses on the role of metabolic dysregulation in the pathogenesis of IPF and is a continuation of our previous studies, investigating metabolic dysregulation as a new target for fibrosis therapy. MDPI 2020-08-07 /pmc/articles/PMC7461042/ /pubmed/32784632 http://dx.doi.org/10.3390/ijms21165663 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bargagli, Elena Refini, Rosa Metella d’Alessandro, Miriana Bergantini, Laura Cameli, Paolo Vantaggiato, Lorenza Bini, Luca Landi, Claudia Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title | Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title_full | Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title_fullStr | Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title_short | Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis |
title_sort | metabolic dysregulation in idiopathic pulmonary fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7461042/ https://www.ncbi.nlm.nih.gov/pubmed/32784632 http://dx.doi.org/10.3390/ijms21165663 |
work_keys_str_mv | AT bargaglielena metabolicdysregulationinidiopathicpulmonaryfibrosis AT refinirosametella metabolicdysregulationinidiopathicpulmonaryfibrosis AT dalessandromiriana metabolicdysregulationinidiopathicpulmonaryfibrosis AT bergantinilaura metabolicdysregulationinidiopathicpulmonaryfibrosis AT camelipaolo metabolicdysregulationinidiopathicpulmonaryfibrosis AT vantaggiatolorenza metabolicdysregulationinidiopathicpulmonaryfibrosis AT biniluca metabolicdysregulationinidiopathicpulmonaryfibrosis AT landiclaudia metabolicdysregulationinidiopathicpulmonaryfibrosis |